How should thyroid function, particularly low free T3 conversion, be monitored and managed in patients receiving immune checkpoint inhibitor therapy?

Monitoring and Management of T3 Conversion in ICI Therapy

In patients receiving immune checkpoint inhibitor therapy, T3 measurement is not routinely recommended for monitoring thyroid function; instead, use TSH and free T4 every 4-6 weeks, reserving T3 testing only for highly symptomatic patients with minimal FT4 elevations during thyrotoxicosis. 1

Standard Monitoring Approach

The 2021 ASCO guidelines establish a clear monitoring framework that does not prioritize T3 conversion assessment:

For Asymptomatic Patients

• Check TSH every 4-6 weeks as routine monitoring during ICI therapy
• FT4 is optional in asymptomatic patients 1

For Symptomatic Patients

• Always measure both TSH and FT4 together for case detection
• This dual testing is critical because TSH alone can miss central hypothyroidism (where TSH may remain normal despite low FT4) 1

Limited Role for T3 Testing

T3 measurement is helpful only in highly symptomatic patients with minimal FT4 elevations during thyrotoxicosis 1. This represents a narrow clinical indication—essentially ruling out T3 toxicosis in Graves' disease when thyrotoxic symptoms are severe but FT4 is only mildly elevated.

Management of Hypothyroidism (Not T3-Focused)

When hypothyroidism develops, treatment follows standard levothyroxine replacement without specific attention to T3 conversion:

Levothyroxine Dosing

• Younger patients (<70 years) without cardiac disease: Start at full replacement dose of approximately 1.6 mcg/kg/day based on ideal body weight 1
• Older patients (≥70 years) or those with cardiac disease/frailty: Start low at 25-50 mcg daily and titrate up 1

Monitoring During Treatment

• Recheck TSH every 6-8 weeks while titrating
• Goal: TSH within reference range
• FT4 can help interpret persistent TSH abnormalities, as TSH normalization may lag behind FT4 1
• Once stable, monitor every 6-12 months or with symptom changes 1

The Emerging T3 Conversion Issue

While guidelines do not address peripheral T3 conversion defects, recent case evidence suggests this may be an underrecognized problem 2. A 2022 case series identified three ICI-treated patients with clinically overt hypothyroidism who were non-responsive to standard levothyroxine therapy. These patients improved with liothyronine (T3) supplementation, suggesting an underlying functional defect in peripheral FT4 to FT3 conversion (supported by SPINA-GD calculations) 2.

When to Suspect T3 Conversion Problems

Consider this rare scenario when:

• Patient remains clinically hypothyroid despite normalized FT4 on levothyroxine
• Levothyroxine dose requirements are unexpectedly high (>1.6 mcg/kg)
• Standard causes of levothyroxine resistance are excluded (malabsorption, nonadherence, drug interactions)

Important Caveat: Proteinuria

In patients receiving combination ICI and tyrosine kinase inhibitor therapy (e.g., lenvatinib + pembrolizumab), significant proteinuria can cause urinary loss of protein-bound thyroid hormone, leading to apparent levothyroxine resistance 3. Check for proteinuria before attributing resistance to conversion defects.

Clinical Pitfalls to Avoid

1. Don't routinely check T3 levels in ICI-related thyroid dysfunction—this is not guideline-supported and adds unnecessary complexity 1

2. Don't miss central hypothyroidism by checking TSH alone in symptomatic patients—always add FT4 1

3. Don't treat elevated TSH immediately if FT4 remains normal in asymptomatic patients during recovery from thyroiditis—monitor for 3-4 weeks as this may resolve spontaneously 1

4. Don't overlook the biphasic pattern: ICI-induced thyroiditis typically presents as initial thyrotoxicosis (lasting weeks) followed by hypothyroidism 1. Monitor thyroid function every 2-3 weeks after thyrotoxicosis diagnosis to catch the transition 1

Practical Algorithm

For routine ICI patients:

• Asymptomatic → TSH every 4-6 weeks
• Symptomatic → TSH + FT4
• If hypothyroid → Start levothyroxine (dose based on age/comorbidities)
• Recheck TSH every 6-8 weeks until stable

For treatment-refractory cases only:

• Verify adherence and exclude malabsorption
• Check for proteinuria (especially with TKI combinations)
• Consider endocrine referral for possible T3 supplementation trial
• Calculate SPINA-GD if available to assess conversion efficiency

The evidence strongly supports that T3 conversion monitoring is not part of standard ICI thyroid management, but clinicians should maintain awareness of this rare complication when patients fail standard levothyroxine therapy 2.